MedFluid

MedFluid is the world’s only startup dedicated to developing diverse point-of-care testing (POCT) precision diagnostics powered by its patented microfluidic technology platform. By integrating proprietary microfluidic cartridges, in-house biochemical reagents, and an AI-driven interpretation system, we have developed two core products: NAST, a solution for antimicrobial susceptibility testing in companion animals, and O-in, a one-stop precision molecular diagnostic system. MedFluid has been recognized with prestigious awards, including First Prize at the InnoVEX 2019 Pitch Contest, selection as a Top 12 Startup at MEDICA 2022, inclusion in Tatler Gen.T 2024, and strong performance at international competitions such as Wolves Summit 2025. Our products have already been exported to multiple countries across Southeast Asia and Europe, demonstrating tangible global market expansion. We are committed to delivering rapid, accurate, and accessible diagnostic solutions, providing a next-generation approach to antimicrobial resistance (AMR) control and precision medicine.